Susceptibility for Entrainment: Role of Ventilator Settings on the Occurrence of Reverse Triggering and Its Physiological Consequences - the SEVeRe Study

NCT ID: NCT06293976

Last Updated: 2025-05-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-30

Study Completion Date

2026-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background: Reverse triggering (RT) is a frequent phenomenon observed in sedated patients under a mechanical ventilation mode called assist-control ventilation. RT is when the ventilator would trigger the patient's respiratory effort instead of the correct order of the patient's respiratory effort triggering the ventilator. Reverse triggering can have negative consequences (loss of protective lung ventilation, and causing double breaths - with the ventilator giving two consecutive breaths and not allowing the patient to exhale) but also offer some protective effects (avoid diaphragm disuse atrophy). The balance of its negative vs positive effects depends on its frequency and magnitude of its associated respiratory effort. Respiratory entrainment is the most often referred mechanism involving a change in patient's rate of breathing effort from that of patient's intrinsic rate to the rate of mechanical insufflation. The specific ventilatory settings associated with or responsible for RT remains unknown.

Aims: To assess in mechanically ventilated critically ill patients the influence of the set respiratory rate (RR) and tidal volume (Vt) on the presence/development of RT and to describe the pattern of respiratory muscle activity during Reverse Triggering (RT).

Methods. 30 adult patients (15 in each group), sedated and under assist-controlled ventilation will be included. Ventilator settings will be modified to modulate the frequency and magnitude of reverse triggering. Initially, with the ventilator on a mode called volume control, which means the ventilator controls the amount of air (tidal volume) and the number of breaths the patients gets every minute (respiratory rate \[RR\]). The tidal volume will be set at the current standard clinical practice setting (6 ml/kg of predicted body weight). The presence of an intrinsic respiratory rate will be assessed with an end-expiratory occlusion maneuver. Next, the number of breaths the ventilator gives per minute (RR) will be changed from 6 breaths less to 6 breaths more, in steps of 2 breaths every minute. The protocol will be repeated again changing the amount of air the patients gets (tidal volume) from 4, 5, 7 and 8 ml/kg. Continuous recordings of airway pressure, flow, esophageal pressure, electrical activity of the diaphragm, main accessory muscles and frontal electroencephalography will be obtained during the protocol and baseline clinical and physiological characteristics and outcomes will be recorded. A validated software will be used to detect RT and measure the intensity and timing of each muscle electrical activity and the magnitude of the inspiratory effort during RT.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants. Critically ill patients (n: 30; aimed recruitment of equal numbers of men and women) aged 18 years or older admitted to the St. Michael's Hospital, Unity Health Toronto, Ontario, Canada.

Inclusion criteria:

* patients intubated for more than 12 hours
* exposed to sedation for at least 6 hours
* with a sedation-agitation score ≤ 4
* and corresponding to one of the following categories based on bedside inspection of ventilator waveforms:

1. patients on assist-control ventilation having reverse triggering at clinical settings (n: 15).
2. patients on assist-control ventilation without reverse triggering at the clinical settings (n: 15).

Exclusion criteria:

* primary severe neurological disorders
* previous lung transplant
* contraindications for esophageal catheter insertion
* current use of continuous neuromuscular blocking agents at the time of the study procedure
* severe metabolic acidosis (pH \< 7.25) at the time of study procedure. Study design. Briefly, first the ventilator Vt is set at 6 ml/kg of predicted body weight (PBW) (i.e., clinical practice recommendation) and either a up to 30sec-long (or two inspiratory efforts) end-expiratory occlusion maneuver will be performed on the ventilator or the patient will be switched to pressure support for 30 - 60 sec (based on discussion with the clinical team) to assess the presence or absence of patient's intrinsic RR.

Secondly, the influence of the ventilator RR on both the occurrence of reverse triggering and the level of effort associated with the reverse triggered breath will be assessed. In random order the ventilator RR will be modified from 6 bpm below up to 6 bpm above the clinical RR in steps of 2 bpm every 1 minute (Figure 1). A 1-minute stage at the patients clinical settings of ventilation in-between each step will be performed to minimize changes in PaCO2.

Thirdly, the influence of the Vt set on the ventilator on both the occurrence of reverse triggering and the level of effort associated with the reverse triggered breath will be assessed. The ventilator Vt will be set to 5 ml/kg PBW, 7 and 8 ml/kg PBW in random order and for each volume, repeat the sequence described in the paragraph above. A 1-minute clinical settings ventilation will be performed in-between each step to minimize changes in PaCO2.

Next, the patient will be returned to their initial clinical settings. Another end-expiratory occlusion of up to 30 seconds (or two inspiratory efforts) or switch the patient to pressure support for 30 - 60 sec (based on discussion with the clinical team) will be performed to search for an intrinsic RR (i.e., intrinsic respiratory drive). If an intrinsic respiratory rate ≥8 breaths per minute is present and P/F ratio is ≥150, it will propose to the clinician to place the patient in pressure support at a level preferred by clinicians for 5 minutes. If the patient tolerates well 5 minutes in pressure support, it be will propose to the clinician to maintain the patient in pressure support ventilation.

The steps described above will be aborted at any point if SpO2 drops below 85% for at least two minutes, mean arterial pressure drops below 60 mmHg, or plateau pressure \>35 cmH2O.

Additionally, the ventilator waveforms and electroencephalography (EEG) will be recorded continuously for the next 24 hours to investigate whether the presence of intrinsic RR was associated with changes in the ventilation mode by the clinician and brain activity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiration, Artificial Reverse Triggering

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients under mechanical ventilation

Patients intubated for more than 12 hours, on assist-control ventilation, not triggering the ventilator with or without reverse triggering, exposed to sedation for at least 6 hours, with a sedation-agitation score ≤ 4.

Group Type EXPERIMENTAL

Changes in the ventilator respiratory rate and tidal volume

Intervention Type OTHER

With the ventilator on volume control and Vt at 6 ml/kg of predicted body weight (PBW) (standard clinical practice), an end-expiratory occlusion of 30 seconds on the ventilator will be performed to search for intrinsic respiratory rate (RR). The set RR will be modified from 6 breaths per minute (bpm) below up to 6 bpm above the clinical RR in steps of 2 bpm every 1 minute (random order). The changes in RR described above will be repeated with Vt set at 5, 7 and 8 ml/kg PBW (random order). The steps described above will be aborted at any point if SpO2 drops below 85% for at least two minutes, mean arterial pressure drops below 60 mmHg, or plateau pressure \>35 cmH2O.

If an intrinsic respiratory rate ≥8 bpm is present and P/F ratio is ≥150, it will be propose to the clinician to place the patient in pressure support at a level preferred by clinicians for 5 minutes. If the patient tolerates well, it will be propose to the clinician to maintain the patient in pressure support ventilation,

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Changes in the ventilator respiratory rate and tidal volume

With the ventilator on volume control and Vt at 6 ml/kg of predicted body weight (PBW) (standard clinical practice), an end-expiratory occlusion of 30 seconds on the ventilator will be performed to search for intrinsic respiratory rate (RR). The set RR will be modified from 6 breaths per minute (bpm) below up to 6 bpm above the clinical RR in steps of 2 bpm every 1 minute (random order). The changes in RR described above will be repeated with Vt set at 5, 7 and 8 ml/kg PBW (random order). The steps described above will be aborted at any point if SpO2 drops below 85% for at least two minutes, mean arterial pressure drops below 60 mmHg, or plateau pressure \>35 cmH2O.

If an intrinsic respiratory rate ≥8 bpm is present and P/F ratio is ≥150, it will be propose to the clinician to place the patient in pressure support at a level preferred by clinicians for 5 minutes. If the patient tolerates well, it will be propose to the clinician to maintain the patient in pressure support ventilation,

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients intubated for more than 12 hours
* On assist-control ventilation, not triggering the ventilator
* Exposed to sedation for at least 6 hours
* With a sedation-agitation score ≤ 4.

Exclusion Criteria

* primary severe neurological disorders
* previous lung transplant
* contraindications for esophageal catheter insertion
* current use of continuous neuromuscular blocking agents at the time of the study procedure
* severe metabolic acidosis (pH \< 7.25) at the time of study procedure.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Unity Health Toronto

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Laurent Brochard

Role: PRINCIPAL_INVESTIGATOR

Unity Health Toronto - St. Michael's Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Unity Health Toronto - St. Michael's Hospital

Toronto, Ontario, Canada

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Antenor Rodrigues

Role: CONTACT

416-864-5686

Irene Telias

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Audery Kim

Role: primary

416-864-5686

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

4506

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.